Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
GRI Bio, Inc. reported a net loss of $5.15 million for the nine months ended September 30, 2026, a significant reduction from the $9.30 million loss in the prior year period, primarily due to lower research and development expenses. The company strengthened its liquidity through an ATM offering, ending the period with $9.47 million in cash and cash equivalents. GRI Bio remains a clinical-stage biopharmaceutical company with an accumulated deficit of $56.84 million and no significant revenue.
Processa Pharmaceuticals reported a significant net loss of $189.8 million for the nine months ended September 30, 2026, primarily driven by a $178.0 million charge for acquired in-process research and development following the acquisition of Vidya Therapeutics. The company significantly strengthened its liquidity position during the period, ending with $180.2 million in cash and cash equivalents following a $200.0 million private placement financing.
Valor Energy Inc reported a significant net loss of $40.8 million for the six months ended September 30, 2026, primarily driven by a $34.1 million non-cash charge for the excess of warrant fair value over offering proceeds. Despite the loss, the company strengthened its cash position to $12.5 million following a $10.2 million net inflow from a Units Private Placement.
Venture Global Senior VP, Development Fory Musser Sells $6.58M of Stock
Fory Musser, Senior VP, Development, sold 500,000 shares of Venture Global, Inc. at $13.16 a share, worth $6.58M in total on Nov 12, 2026. Shares held after the trade: 0 (-100.0%).
Health In Tech, Inc. has prepared a formal investor presentation deck to be used by management at upcoming conferences and meetings. The presentation highlights the company's AI-powered marketplace platform designed to help small- and medium-sized businesses access self-funded health plans. The filing includes the full slide deck as Exhibit 99.1 for investor review.
Monolithic Power Systems CFO Frank Anthony Balow III Sells $28.7K of Stock
Frank Anthony Balow III, CFO, sold 20 shares of Monolithic Power Systems, Inc. at $1,434.31 a share, worth $28.7K in total on Nov 11, 2026. Shares held after the trade: 2,921 (-0.7%).
Astrotech reported a net loss of $2.9 million for the quarter ended September 30, 2026, compared to a $3.5 million loss in the prior year. Revenue decreased slightly to $274 thousand, while the company maintained a cash position of $5.6 million following an 'at-the-market' share issuance that raised $467 thousand.
Health In Tech, Inc. announced a leadership transition separating the roles of Executive Chairman and Chief Executive Officer. Founder Tim Johnson will serve as Executive Chairman focusing on long-term strategy and innovation, while Sanjay Shrestha has been appointed as the new CEO to lead day-to-day operations and commercial execution.
Kairos Pharma, Ltd. reported a net loss of $5.03 million for the nine months ended September 30, 2026, compared to a $4.08 million loss in the prior year period. The company remains in the development stage with no revenue, and its cash position decreased to $3.13 million as of September 30, 2026, from $4.49 million at year-end 2025.
Cerenome, Inc. reported a net loss of $24.6 million for the nine months ended September 30, 2026, compared to a $16.7 million loss in the prior year period. While the company introduced diagnostic revenue of $0.7 million, total revenue decreased due to lower grant revenue, and operating expenses nearly doubled to $25.8 million.
Beasley Broadcast Group reported third quarter 2026 net revenue of $42.8 million, a 16.1% decrease year-over-year driven by weakness in national and local agency advertising. The company reported a net loss of $12.1 million for the quarter but highlighted improved digital operating margins of 32% and the completion of asset sales generating over $10 million in proceeds subsequent to quarter-end.
Meridian Insider Kenneth Thomas Warriner Buys $16.2K of Stock
Kenneth Thomas Warriner bought 1,000 shares of Meridian Corp at $16.18 a share, worth $16.2K in total on Nov 13, 2026. Shares held after the trade: 4,050 (+32.8%).
Health In Tech reported Q3 2026 revenue of $6.6 million and a net loss of $7.1 million, which included a $5.3 million provision for credit losses. The company highlighted a 15.9% year-over-year growth in distribution partners and a revenue pipeline of $156.4 million as of late October.
Term
Q3 2026
“It is a privilege to lead Health In Tech into its next chapter, and I want to thank Tim Johnson, our founder and Executive Chairman, and the Board for their confidence. Throughout my career, I have focused on scaling businesses, developing growth strategies, and leveraging capital markets to support long-term value creation. I have substantial operational experience scaling new products from incubation to meaningful commercial scale, building”
Sanjay Shrestha, Chief Executive Officer of Health In Tech
Intellia Therapeutics hosted a webcast and filed a formal investor presentation titled 'Readying Lonvo-z for Patients with HAE.' The presentation focused on the commercial potential and clinical data for lonvoguran ziclumeran (lonvo-z), a CRISPR-based therapy for hereditary angioedema.
National Health Investors entered into new indemnification agreements with its directors and executive officers. The agreements obligate the company to indemnify these individuals to the maximum extent permitted by Maryland law for expenses and liabilities incurred due to their status as company officials, provided they acted in good faith. This is a standard corporate governance and compensatory arrangement to protect leadership from personal liability.
Cheetah Net Supply Chain Service Inc. reported a significant increase in revenue to $4.52 million for the nine months ended September 30, 2026, compared to $1.20 million in the prior year. Despite this growth, the company realized a net loss of $3.09 million, driven by high operating expenses and a $2.78 million loss related to the change in fair value of an acquisition-related contingent consideration asset.
Globalfoundries CLO Samak L. Azar Sells $14K of Stock
Samak L. Azar, CLO, sold 335 shares of Globalfoundries Inc. at $41.86 a share, worth $14K in total on Nov 12, 2026. Shares held after the trade: 6,784 (-4.7%).
DocGo Inc. entered into a Transition Services and Separation Agreement with CEO Lee Bienstock, who will step down on March 31, 2027. During the transition period, Bienstock will receive a monthly salary of $90,000 and accelerated monthly equity vesting, followed by a $785,000 severance payment. The company is currently conducting a search for a successor CEO as Bienstock's original employment agreement was set to expire at the end of 2026.
Circle Internet Group Insider Danita K. Ostling Sells $97.1K of Stock
Danita K. Ostling sold 1,500 shares of Circle Internet Group, Inc. at $64.74 a share, worth $97.1K in total on Nov 12, 2026. Shares held after the trade: 3,108 (-32.6%).
LivaNova CFO Alex Shvartsburg Sells $227K of Stock
Alex Shvartsburg, CFO, sold 2,500 shares of LivaNova PLC at $90.91 a share, worth $227K in total on Nov 12, 2026. Shares held after the trade: 42,147 (-5.6%).
Accuray completed a $55 million financing transaction with its primary lender TCW, involving the issuance of 55,000 shares of Series A Convertible Preferred Stock. The deal includes $15 million in new cash capital and the conversion of $40 million of existing debt into equity, significantly deleveraging the balance sheet.
Contango Silver & Gold Inc. entered into a Controlled Equity Offering Sales Agreement to establish an at-the-market (ATM) offering program. The company may sell shares of common stock from time to time with an aggregate offering price of up to $75 million. Cantor Fitzgerald & Co. is acting as the lead agent for the program.
Healthcare Triangle, Inc. reported a significant revenue increase to $28.2 million for the nine months ended September 30, 2026, compared to $10.8 million in the prior year, driven by business expansion. However, the company continues to operate at a loss, with a net loss from operations of $9.7 million for the period and a total asset base that grew to $72.7 million following substantial increases in intangible assets.
Royal Caribbean Cruises Insider Arne Alexander Wilhelmsen Sells $62.1M of Stock
Arne Alexander Wilhelmsen sold 185,000 shares of Royal Caribbean Cruises Ltd at $322.30 to $341.13 a share (average $335.73) in 14 transactions, worth $62.1M in total between Nov 11, 2026 and Nov 12, 2026. Shares held after the trade: 15,524,236 (-0.0%).
Fly-E Group, Inc. reported a significant decline in revenue to $5.34 million for the six months ended September 30, 2026, compared to $9.24 million in the prior year period. The company's net loss widened to $5.68 million for the same period, driven by decreased gross profit and high general and administrative expenses, raising concerns about its ability to continue as a going concern.
Presidio Property Trust reported a decrease in total revenue to $10.57 million for the nine months ended September 30, 2026, compared to $12.70 million in the prior year period. The company experienced a significant reduction in total assets from $122.1 million at year-end 2025 to $86.3 million, primarily driven by a decrease in real estate assets held for investment.
Scientific Industries reported a net loss of $2.35 million for the nine months ended September 30, 2026, compared to a net income of $0.69 million in the prior year period. While revenues increased to $4.05 million from $3.43 million, the prior year's profitability was primarily driven by a larger gain on the disposition of discontinued operations.
Mobiquity Technologies reported a significant revenue increase to $334,896 for the nine months ended September 30, 2026, compared to $160,795 in the prior year. However, net loss widened to $8.6 million due to higher general and administrative expenses, resulting in a total stockholders' deficit of $221,189.
Positron Corp filed its Form 10-Q for the quarterly period ended September 30, 2026, detailing its financial performance and operational progress in the molecular imaging industry. The report highlights the company's focus on its PET imaging systems and the development of its radiopharmaceutical business segments.
Calidi Biotherapeutics reported a net loss of $11.9 million for the nine months ended September 30, 2026, compared to a $16.0 million loss in the prior year period. The company maintained a cash balance of $3.9 million as of September 30, 2026, and completed a 1-for-16 reverse stock split in July 2026 to adjust its capital structure.